3487-81-8

Upstream product

• 262-12-4 dioxin 
• 21905-73-7 2-carboxy-2'-methoxydiphenyl ether 
• 109-99-9 tetrahydrofuran 
• 60-29-7 diethyl ether 
• 79365-16-5 2-(2'-methoxyphenoxy)benzonitrile 
• 90-05-1 2-methoxy-phenol 
• 394-47-8 2-fluorobenzonitrile 
• 1089144-10-4 2-(2-Benzyloxy-phenoxy)-benzoic acid benzyl ester 
• 26321-29-9 2-methoxy-2'-methyldiphenyl ether 

Downstream Products

• 3487-84-1 2-(2-hydroxy-phenoxy)-benzoic acid methyl ester 
• 257-08-9 Depsidan 
• 100397-01-1 2-(2-hydroxy-phenoxy)-benzyl alcohol 
• 855400-98-5 2-(2-bromomethyl-phenoxy)-phenol 

Relevant academic research and scientific papers

Efficient Aryl Migration from an Aryl Ether to a Carboxylic Acid Group To Form an Ester by Visible-Light Photoredox Catalysis

We have developed a highly efficient aryl migration from an aryl ether to a carboxylic acid group through retro-Smiles rearrangement by visible-light photoredox catalysis at ambient temperature. Transition metals and a stoichiometric oxidant and base are avoided in the transformation. Inspired by the high efficiency of this transformation and the fundamental importance of C?O bond cleavage, we developed a novel approach to the C?O cleavage of a biaryl ether to form two phenolic compounds, as demonstrated by a one-pot, two-step gram-scale reaction under mild conditions. The aryl migration exhibits broad scope and can be applied to the synthesis of pharmaceutical compounds, such as guacetisal. Primary mechanistic studies indicate that the catalytic cycle occurs by a reductive quenching pathway.

COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME

The invention discloses a new use of a class of heptacyclic compounds in the preparation of formulations for the prevention and treatment of diabetes and metabolic syndromes; the present invention also discloses a new class of heptacyclic compounds; the present invention also discloses a process for preparing the heptacyclic compounds and a composition containing the same. The heptacyclic compounds of the present invention can be used to effectively preventing or treating diseases such as diabetes and metabolic syndromes.

Leukotriene antagonists

This invention provides tricyclic derivatives which are leukotriene B4 antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes